Bleeding Disorders

Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment

After frontline treatment with corticosteroids fails to elicit a response in patients with chronic immune thrombocytopenia (cITP), the choice between rituximab or thrombopoietin receptor...
How I Treat In Brief

How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease

Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...

Updated Romiplostim Label Supports Earlier Use in ITP

The U.S. Food and Drug Administration (FDA) granted approval to a supplemental Biologics License Application for romiplostim that updates the drug’s label to include...
WIB_icon

Emicizumab Lowers Bleeding Rates in Children With Hemophilia A and Inhibitors

Once-weekly treatment with emicizumab prophylaxis led to low bleeding rates in children with hemophilia A and factor VIII (FVIII) inhibitors, with more than three-quarters...
WIB_icon

Moderate-Intensity Endurance Training Improves Skeletal Microvasculature in Patients with Sickle Cell Disease

An endurance exercise training program of moderate intensity may reverse some of the microvascular deficits of skeletal microvasculature in patients with sickle cell disease...
WIB_icon

The Fewer Transfusions, the Better for Newborns With Thrombocytopenia

Newborns with thrombocytopenia had a lower risk of death or bleeding if they received platelet transfusions according to a lower 25×109/L threshold rather than...

CRISPR Shows Early Benefit for Patients with Sickle Cell Disease and Beta Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals have reported that the first two patients to receive the experimental treatment for sickle cell disease (SCD) and beta...
Sickle cell anemia

FDA Approves Crizanlizumab-tmca for Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) has approved crizanlizumab-tmca, a monoclonal antibody against the P-selectin glycoprotein that is expressed on activated endothelial cells...

Heparin-Induced Thrombocytopenia Does Not Appear to Protect Against Major Bleeding

Patients with heparin-induced thrombocytopenia (HIT), a prothrombotic complication of heparin exposure, are believed to be protected against anticoagulant-associated bleeding, but results from a retrospective analysis...
WIB_icon

Older Patients with iTTP Have Delayed Diagnosis and Higher Mortality Than Younger Counterparts

Older patients diagnosed with immune thrombotic thrombocytopenic purpura (iTTP) have worse short- and long-term mortality compared with younger patients and the general population, according...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.